<DOC>
	<DOCNO>NCT01324518</DOCNO>
	<brief_summary>The purpose study determine whether ORM-12741 safe effective treatment Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy ORM-12741 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The purpose study determine whether ORM-12741 safe effective treatment cognitive behavioral symptom patient Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Informed consent obtain patient legally acceptable representative , require Informed consent obtain caregiver Males females 5590 year Diagnosis probable Alzheimer 's disease , history progressive cognitive deterioration Brain imaging consistent Alzheimer 's disease Minimental state examination score 1221 Treated donepezil , rivastigmine galantamine At least mild level behavioral symptom Other type dementia Modified Hachinski Ischemia Score &gt; 4 Use memantine , antipsychotic , anticholinergic medication benzodiazepine ( max 3 nights/week ) within 2 month Changes antidepressant dose within 2 month Use psychotropic agent Myocardial infarction within past 2 year Malignancy within past 5 year Suicidal ideation , risk suicide History alcoholism drug abuse within 5 year Clinically significant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , neurological psychiatric disorder major concurrent illness Specific finding brain image Abnormal finding heart rate , blood pressure , ECG , laboratory test , physical examination ; orthostatic hypotension Blood donation participation drug study within 60 day Previous AD immunotherapy treatment Patient complete computerise cognitive training Patients reside skilled nursing facility Patients able swallow capsule</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>